Table 2.
Baseline characteristics for high-risk patients with CAP and HAP (excluding VAP) (CE population)
| High-risk CAP | ||
| Ceftobiprole (n = 193) n (%) |
Ceftriaxone ± linezolid (n = 205) n (%) |
|
| Male | 115 (59.6) | 123 (60.0) |
| Age ≥ 65 years | 88 (45.6) | 92 (44.9) |
| Sepsis | 123 (63.7) | 135 (65.9) |
| Pre-study antibiotics within 24 h | 97 (50.3) | 121 (59.0) |
| Valid pathogen at baseline | 59 (30.6) | 68 (33.2) |
| Patients with linezolid usea | 19 (9.8) | 30 (14.6) |
| High-risk HAP (excluding VAP) | ||
| Ceftobiprole (n = 169) n (%) |
Ceftazidime plus linezolid (n = 138) n (%) |
|
| Male | 117 (69.2) | 80 (58.0) |
| Age ≥ 65 years | 106 (62.7) | 86 (62.3) |
| Sepsis | 122 (72.2) | 109 (79.0) |
| APACHE score ≥ 15 | 67 (39.6) | 59 (42.8) |
| Ventilation at baseline | 22 (13.0) | 24 (17.4) |
| Pre-study antibiotics within 24 h | 101 (59.8) | 81 (58.7) |
| Valid pathogen at baseline | 100 (59.2) | 89 (64.5) |
| Anti-pseudomonal antibioticsb | 24 (14.2) | 16 (11.6) |
aCAP patients suspected of MRSA infection received add-on linezolid if randomised to ceftriaxone; if randomised to ceftobiprole, they received add-on placebo instead of linezolid
bEmpirical treatment with antibiotic therapy was added to the study treatment for 48 h in patients with a suspected infection due to Pseudomonas aeruginosa or for 5–7 days in patients with proven infection due to Pseudomonas aeruginosa
APACHE Acute Physiology and Chronic Health Evaluation, CAP community-acquired pneumonia, CE clinically evaluable, HAP hospital-acquired pneumonia, MRSA methicillin-resistant Staphylococcus aureus, VAP ventilator-associated pneumonia